Cellectis (NASDAQ:CLLS) Price Target Cut to $13.00

Cellectis (NASDAQ:CLLS – Get Rating) had its target price lowered by Oppenheimer from $16.00 to $13.00 in a research report issued to clients and investors on Monday, Benzinga reports. The firm currently has an “outperform” rating on the biotechnology company’s stock.

Several other research firms have also recently commented on CLLS. JMP Securities cut their price target on Cellectis from $11.00 to $6.00 and set a “market outperform” rating for the company in a report on Thursday, January 19th. Citigroup cut their price target on Cellectis from $36.00 to $24.00 in a report on Wednesday, December 14th. Finally, StockNews.com raised Cellectis from a “sell” rating to a “hold” rating in a report on Saturday, December 3rd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $10.33.

Cellectis Price Performance

Shares of Cellectis stock opened at $1.98 on Monday. Cellectis has a 12 month low of $1.83 and a 12 month high of $5.04. The company has a debt-to-equity ratio of 0.16, a current ratio of 2.28 and a quick ratio of 2.65. The stock has a market capitalization of $110.05 million, a P/E ratio of -0.85 and a beta of 2.13. The business has a 50 day simple moving average of $2.68 and a two-hundred day simple moving average of $2.54.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in CLLS. Envestnet Asset Management Inc. grew its position in Cellectis by 19.2% in the first quarter. Envestnet Asset Management Inc. now owns 20,501 shares of the biotechnology company’s stock worth $93,000 after acquiring an additional 3,305 shares during the period. State Street Corp grew its position in Cellectis by 3.7% in the first quarter. State Street Corp now owns 119,561 shares of the biotechnology company’s stock worth $543,000 after acquiring an additional 4,297 shares during the period. Jane Street Group LLC grew its position in Cellectis by 166.5% in the first quarter. Jane Street Group LLC now owns 603,253 shares of the biotechnology company’s stock worth $2,789,000 after acquiring an additional 376,862 shares during the period. Principal Financial Group Inc. grew its position in Cellectis by 11.0% in the second quarter. Principal Financial Group Inc. now owns 1,348,312 shares of the biotechnology company’s stock worth $3,816,000 after acquiring an additional 133,587 shares during the period. Finally, Virtu Financial LLC purchased a new position in Cellectis in the second quarter worth approximately $46,000. 22.61% of the stock is currently owned by hedge funds and other institutional investors.

Cellectis Company Profile

(Get Rating)

Cellectis SA operates as a clinical stage biotechnological company. The firm operates through the segments: Therapeutics and Plants. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and monogenic diseases. The Plants segment focuses on using Calyxt’s proprietary PlantSpringTM technology platform to engineer plant metabolism to produce innovative, high-value, and sustainable materials and products for use in helping customers meet their sustainability targets and financial goals.